linjc16/ctgov huggingface dataset:
Experience in Borderline Ovarian Tumors

Study Overview
=================
Brief Summary
-----------------
Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent an independent disease entity among epithelial ovarian cancers. The present study aimed to report the 8-year experience of a single center on the management and outcomes of consecutive BOTs patients. From January 2010 to December 2017, all patients with BOTs undergoing surgical treatment were included. Demographic, clinical, and pathological data were reviewed retrospectively.

Official Title
-----------------
Borderline Ovarian Tumors: Results of a Retrospective, Single-center Experience

Conditions
-----------------
Borderline Ovarian Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years, Patients affected by borderline ovarian tumors (BOT) of any histological type and any FIGO stage, Women undergoing surgical treatment with both laparoscopic and laparotomic approaches. Exclusion Criteria: - Women affected by ovarian cancers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oncological outcome | Patients who underwent surgery for BOT | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Conservative surgery, Micropapillary patterns, Surgical staging
The Impact of a Transitional Care Management Programme on the Migration Stress of Family Members of Patients

Study Overview
=================
Brief Summary
-----------------
This study investigated the impact of the establishment and application of the health care-family-environment linkage mechanism on the level of migration stress, coping styles and care satisfaction of families of patients transferred from the EICU, in order to provide a reference for improving the physical and psychological health of families and to promote the role of family members in the social support of patients transferred out of this category.

Official Title
-----------------
The Impact of a Transitional Care Management Programme on the Migration Stress of Family Members of Patients Transferred Out of the EICU Under the Health Care-family-environment Linkage Model

Conditions
-----------------
Stress

Intervention / Treatment
-----------------
* Procedure: EICU Transfer Routine Care
* Procedure: Implementing interventions based on a 'health care-family-environment' linkage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Family members of trauma patients scheduled to be transferred from the EICU to a general unit within 24h; Family members of patients aged ≥ 18 years; Family members who are responsible for the main care tasks and medical decisions of the patient during hospitalisation; Family members of patients with clear language and good communication skills; Families of patients who volunteered to participate in this study. Exclusion Criteria: Family members of patients temporarily transferred out of the EICU or temporarily discharged from trauma Families of patients who voluntarily request termination of treatment; Family members of patients with cognitive impairment, speech impairment or mental abnormalities.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Control group<br> | Procedure: EICU Transfer Routine Care<br>* EICU Transfer Routine Care<br>|
| Experimental: Experimental group<br> | Procedure: Implementing interventions based on a 'health care-family-environment' linkage<br>* Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stress assessment | Stress assessment assessed by ICU Transfer Stress Assessment Scale for Families of Patients Transferring Out | 48 hours |
Video Documented PBS-Score in Children With Clubfoot

Study Overview
=================
Brief Summary
-----------------
Evaluate agreement and inter-rater reliability of PBS-score assessments based on video documented material.

Detailed Description
-----------------
120 children with idiopathic clubfoot will be included from four different countries 30 patients from each participating center. Inclusion criteria include: age 4-14 years, diagnosis of idiopathic clubfoot, ability to walk 10 m repeatedly, and ability to communicate verbally (and in writing for caregivers) in Swedish, English, Portuguese, Urdu, or Pashto. All items of the PBS-score will be documented using video recordings. Six to eight senior orthopedic surgeons will score a total of 90 children each, not the children from their center of employment, according to the PBS-score based on videos. Collaborating centers include Karolinska University Hospital, Sweden, Hospital Pequeno Príncipe, Brazil, and Hayatabad Medical Complex, Orthopaedic Unit, Peshawar, Pakistan.

Official Title
-----------------
Agreement and Inter-rater Reliability of Video Documented PBS-Score - An International Cross-sectional Multicenter Study

Conditions
-----------------
PBS, Clubfoot

Intervention / Treatment
-----------------
* Other: Score assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clubfoot Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Score assessment|PBS Score|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PBS Score agreement and inter-rater reliability | PBS Score is a tool to grade the severity of clubfoot recurrence in the walking child, and was proposed to serve as an instrument to guide treatment. The sum of all points for all signs is scored between 7 and 18. | 1 year |
Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer

Study Overview
=================
Brief Summary
-----------------
Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning. The study aims to apply radiomics for the prediction of response to neoadjuvant therapy.

Official Title
-----------------
Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer

Conditions
-----------------
Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction

Intervention / Treatment
-----------------
* Radiation: CT scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with locally advanced stomach cancer undergoing neoadjuvant chemotherapy and gastrectomy between January 2005 and August 2022 Exclusion Criteria: Siewert 1 tumors; Patients who have received neoadjuvant with the addition of a biological drug; Patients who have received radiotherapy; Patients without staging CT scan or with insufficient image quality in terms of phases performed, pixel spacing, slide thickness (mandatorily: > 5 mm) or artefacts.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: CT scan|All pre-operative CT scan collected|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use of radiomics | Apply radiomics for predicting response to neoadjuvant therapy. | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stomach cancer, esophagogastric junction., locally advanced carcinoma of the stomach, radiomics
Video Vitals and Biomarkers

Study Overview
=================
Brief Summary
-----------------
The investigators are doing this research to study the ability of mobile devices to measure vital signs and biomarkers from video as compared to standard-of-care clinical office tools.

Official Title
-----------------
Measuring Vital Signs and Biomarkers From Mobile Device Videos

Conditions
-----------------
Adults 18 Years and Older (no Other Exclusion Criteria)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be able to stay in a seated position for 30 minutes Must be able to participate in a venous blood draw Exclusion Criteria: Condition that prevents prolonged seated position Condition that restricts ability to provide venous blood sample

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate in beats per minute |  | 2 minutes | 
| Blood pressure (systolic/diastolic) in millimeters of mercury (mmHg) |  | 2 minutes | 
| Respiration rate in breaths per minute |  | 2 minutes | 
| Oxygen saturation in SpO2 percentage |  | 2 minutes |
Role of Placental Invasion Index in Decision Making of Placenta Accreta

Study Overview
=================
Brief Summary
-----------------
This study will be conducted on women who have a diagnosis of placenta previ and using ultrasound to make the placenta invasion index and compare the accuracy of the diagnosis during the caesarean section whether it is accreta or not with determining the site and depth of invasion

Detailed Description
-----------------
This study will be conducted on women who have a diagnosis of placenta previ and using ultrasound to make the placenta invasion index and compare the accuracy of the diagnosis during the caesarean section whether it is accreta or not with determining the site and depth of invasion and whether there is injury occurred in the urinary system and Determining the amount of blood transfusion and admission of intensive care, or whether the patient death

Official Title
-----------------
Role of Placental Invasion Index in Decision Making of Placenta Accreta

Conditions
-----------------
Placenta Accreta

Intervention / Treatment
-----------------
* Other: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all placenta previa and low laying placenta will be included Exclusion Criteria: patient with sever attack
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Ultrasound|Use ultrasound to make placental invasion index|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Role of placental invasion index in decision making of placenta accreta | Use of ultrasound to make placenta invasion index and compare it intraoperative | 1 year |
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections

Study Overview
=================
Brief Summary
-----------------
The aim of this retrospective observational study is to evaluate the efficacy of antibiotic therapy with dalbavancin in patients presenting with infection on prosthetic devices. The main questions the study aims to answer are: What is the proportion of patients with early discontinuation of dalbavancin therapy? What are the reasons for early discontinuation of antibiotic treatment? What adverse events do patients report? The study is based on data collected as part of routine care practices. Translated with www.DeepL.com/Translator (free version)

Official Title
-----------------
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections

Conditions
-----------------
Prosthesis-related Infections

Intervention / Treatment
-----------------
* Drug: Dalbavancin Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with inextricable and/or inoperable osteoarticular or vascular prosthetic material. Patients requiring suppressive antibiotic therapy (>6 months) with dalbavancin. Exclusion Criteria: Patients who are protected adult; Patients who are minors; Patients having expressed their opposition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dalbavancin Injection|Dalbavancin as long-term suppressive therapy.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy of suppressive Dalbavancin therapy | Proportion of patients successfully treated with Dalbavancin. The efficacy of suppressive therapy will be defined over a two-year period after initiation of treatment as the combination of the following criteria: Clinical control of infection : Absence of local inflammatory signs (erythema, discharge, edema, pain) ; Absence of general signs (hyperthermia: T°>38 or hypothermia T°< 36°); Biological control: o CRP negative (<5mg/l) ; | two-year follow-up after initiation of suppressive therapy with Dalbavancin |
Study on the Development of Neonatal Cerebral Blood Flow Based on Ultrafast Ultrasound Doppler Imaging

Study Overview
=================
Brief Summary
-----------------
Recently, with the development of perinatal medicine in China, the establishment of neonatal intensive care unit (NICU) and the improvement of respiratory support technology, the survival rate of preterm and term neonates has been significantly improved. However, the brain development of preterm neonates is incomplete compared with that of full-term neonates. Therefore, during the extrauterine cultivation of preterm neonates, clinical intervention should be carried out according to their brain development to achieve the same development status as that of full-term neonates. There are many clinical inspection methods to monitor the brain development of preterm neonates, such as EEG, functional near-infrared spectroscopy imaging, etc. However, these technologies cannot assess the brain development of premature infants systematically and completely. Because of the existence of neurovascular coupling, brain function and cerebral blood flow are closely related, so the detection of cerebral blood flow can reflect brain development and brain function. Ultrafast ultrasound power Doppler imaging technology is an emerging, real-time, high-resolution microvascular imaging technology. In this study, we first used ultrafast ultrasound power Doppler imaging technology to image the cerebral blood flow of preterm neonates at different gestational ages to evaluate the development of cerebral blood flow of preterm and term neonates and provide guidance for the clinical intervention of preterm neonates.

Official Title
-----------------
Study on the Development of Neonatal Cerebral Blood Flow Based on Ultrafast Ultrasound Doppler Imaging

Conditions
-----------------
Premature Birth

Intervention / Treatment
-----------------
* Diagnostic Test: ultrafast ultrasound power Doppler imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neonates without cerebral diseases Exclusion Criteria: neonates with cerebral diseases

Ages Eligible for Study
-----------------
Minimum Age: 24 Weeks
Maximum Age: 40 Weeks

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| mature<br> | Diagnostic Test: ultrafast ultrasound power Doppler imaging<br>* ultrafast ultrasound power Doppler imaging for neonatal brain microvessels<br>|
| preterm<br> | Diagnostic Test: ultrafast ultrasound power Doppler imaging<br>* ultrafast ultrasound power Doppler imaging for neonatal brain microvessels<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intrauterine cerebral blood flow development of neonates |  | 30 min | 
| Extrauterine cerebral blood flow development of neonates |  | 30 min |
Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture

Study Overview
=================
Brief Summary
-----------------
This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD), based on usual care, to gain a more in-depth knowledge of the natural history and the treatment outcomes of Dupuytren's Contracture (DC) to evaluate the management of DC.

Detailed Description
-----------------
Each participant of the study will have their data collected from the date of confirmed diagnosis of DC to the date of enrollment in the registry, post consent. Data will be collected from the participants clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.

Official Title
-----------------
Generating Real-world Ambispective Data to Study Participant Treatment Outcomes for Dupuytren's Contracture

Conditions
-----------------
Dupuytren's Contracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Any adult with a confirmed clinical diagnosis of DC. Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment. Willing to participate in the registry (including completion of ePROs) and complete the informed consent form. Having received DC treatment, either non-surgical or surgical, within 2 weeks before enrollment, at enrollment or any time after the date of enrollment or not having received DC treatment after confirmed diagnosis of DC. Able to participate in English based registry. Key Exclusion criteria: Not having a clinical diagnosis of DC. Age less than 18 years. Do not provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Receiving Each Treatment Type for DC |  | Up to 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Michigan Hand Questionnaire (MHQ) Scale Score |  | Up to 36 months | 
| Change from Baseline in European Quality of Life Five Dimension (EQ-5D) Questionnaire Score |  | Up to 36 months | 
| Change from Baseline in Unité Rhumatologique des Affections de la Main (URAM) Scale Score |  | Up to 36 months | 
| Participant Satisfaction Questionnaire |  | Up to 36 months | 
| Number of Participants Receiving Post-Procedural Care by the Treating Physician |  | Up to 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Real world data, Retrospective, Prospective, Registry
Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials

Study Overview
=================
Brief Summary
-----------------
Clinical trials, specifically focused on atopic dermatitis, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

Official Title
-----------------
Understanding Patient Engagement Trends in Atopic Dermatitis Clinical Research

Conditions
-----------------
Atopic Dermatitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to understand and the willingness to sign a written informed consent document Participant must be 18 years of age or older Confirmed diagnosis of atopic dermatitis Exclusion Criteria: Enrolled in another research study Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study Inability to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of atopic dermatitis patients who decide to enroll in a clinical research |  | 3 months | 
| Rate of atopic dermatitis patients who remain in clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atopic dermatitis